Co-Diagnostics (HAM:C970) Quality Rank


HAM:C970 Co-Diagnostics Inc HAM:C970
64 GF Score
Price €5.55
GF Value €4.51
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Co-Diagnostics Quality Rank Related Terms

HAM:C970
64GF Score
Co-Diagnostics Inc HAM:C970
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Co-Diagnostics (HAM:C970) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued. The current stock price of €5.55 is trading 23.1% above its estimated GF Value™ of €4.51.

Key valuation signals for HAM:C970:

  • Quality Rank:
  • GF Value™: €4.51 vs. price of €5.55 (23.1% above fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Co-Diagnostics Business Description

Other Exchanges CODX:USA0A50:UK
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
64GF Score

Get the complete analysis for HAM:C970

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.55
Price
€4.51
GF Value